Omega 3
Prescription Drug Market
Request Sample Report
Omega 3 Prescription Drug Market Size and Growth
The Omega-3 prescription drug market is experiencing significant growth, driven by increasing awareness of cardiovascular health and chronic inflammation. The global market size was valued at approximately $8 billion in 2023, with a projected CAGR of 7% through 2030, reflecting rising demand for dietary supplements and prescription omega-3 formulations.
Companies Covered (Covid 19 Impact Covered)
◍ "Abbott"
◍ "Amarin Pharmaceuticals Ireland Ltd."
◍ "GSK plc (GlaxoSmithKline plc)"
◍ "Natrapharm
◍ Inc. (Patriot Pharmaceutical Corp.)"
◍ "Viatris
◍ Inc."
◍ "Grupo Ferrer Internacional
◍ S.A."
◍ "Camber Pharmaceuticals
◍ Inc."
◍ "Dr. Reddy’s Laboratories Ltd."
◍ "Zydus Group"
◍ "Hikma Pharmaceuticals PLC"
The Omega 3 prescription drug market is competitive, with key players like Abbott, Amarin, and GSK focusing on innovation and marketing. Companies enhance market growth through effective promotions, expanding product lines, and targeting healthcare professionals. Specific sales revenues include:
- Amarin: Approximately $220 million (2022).
- Abbott: $12.2 billion (Q2 2023).
Additional companies include Viatris, Grupo Ferrer, Camber, Dr. Reddy's, Zydus, and Hikma, contributing to diverse offerings and global reach.
Request Sample Report
Market Segmentation
By Application
◍ "Hospital Pharmacy"
◍ "Retail Pharmacy"
By Product
◍ "Vascepa" ◍ "Lovaza"
◍ "Online Pharmacy" Request Sample Report
◍ "Others"
Market Growth
Request Sample Report
$ X Billion USD
